Erythemic States: A Comprehensive Report on the History, Science, and Clinical Significance of Erythema

Introduction: Defining "Erythemic" and Understanding Erythema as a Cornerstone of Dermatology

The term "erythemic" is the adjectival form of "erythema," a foundational concept in medicine and dermatology.¹ It describes a state or condition characterized by erythema, which is the observable redness of the skin or mucous membranes. It is crucial to clarify from the outset that erythema is a clinical sign—a visible manifestation of an underlying biological process—and not a substance that can be grown, prepared, or purchased. This report will explore the vast medical, historical, and scientific universe this term encompasses, providing an exhaustive informational resource on erythemic states.

The word itself offers a window into its ancient observational roots. "Erythema" entered the medical lexicon from New Latin, which borrowed it directly from the Greek erythēma, meaning "a redness on the skin" or a "blush".³ This, in turn, derives from the verb

erythainein, "to become red," and ultimately from the adjective erythros, meaning "red".¹ Linguistically,

erythros traces back to the Proto-Indo-European (PIE) root **reudh-*, for "red" or "ruddy." Remarkably, *reudh- is the only color for which a definitive, common PIE root word has been found, underscoring the fundamental nature of redness in ancient human observation and language.³

Beyond its etymology, erythema holds a central place in medical history as one of the cardinal signs of inflammation. The Roman encyclopedist Aulus Cornelius Celsus, writing in the 1st century AD, first described the four classic signs of inflammation: rubor (redness), calor (heat), tumor (swelling), and dolor (pain).⁶ Erythema is the clinical manifestation of

rubor. This positions it not merely as a superficial color change but as a vital clue to a vast array of physiological processes, from simple skin irritation to complex, life-threatening systemic diseases. This report will navigate the history of erythema's recognition in medicine, delve into the intricate science of how and why skin becomes red, provide a detailed taxonomy of the major erythemic conditions, and offer practical guidance for patients experiencing this common but significant clinical sign.

Section 1: The Historical Lens: Charting the Recognition of Erythema in Medicine

The journey to understand erythema mirrors the evolution of medicine itself—from ancient, generalized descriptions of skin ailments to the sophisticated, mechanism-based field of modern dermatology. The recognition of "redness" as a specific diagnostic sign was a slow process, hampered for centuries by a medical tradition that largely overlooked the skin as a complex organ.

From Ancient Observation to Early Classification

In ancient Greek and Roman medicine, the skin was primarily viewed as a simple "casing" or "hide"—the Greek dérma and Latin cutis both reflect this utilitarian concept.⁸ Consequently, skin diseases were often described in broad, functional terms rather than by specific morphology. Hippocrates (c. 400 BC), for instance, described destructive cutaneous ulcers under the heading of

herpes esthiomenos ("eating herpes"), a term that likely encompassed a range of unrelated conditions.⁹ This descriptive imprecision continued for centuries. In 916 AD, Herbernus of Tours was the first to apply the term

lupus (Latin for "wolf") to a skin disease, presumably to describe its voracious, ulcerative nature.⁹ For nearly a millennium, terms like

lupus and herpes esthiomenos were used almost interchangeably for various destructive facial lesions.⁹

The true dawn of modern dermatology as a specialized discipline arrived in the late 18th and early 19th centuries, driven by a new emphasis on systematic classification. In London, Robert Willan's work, On Cutaneous Diseases (published 1798–1808), was a landmark achievement. He created one of the first logical, morphological classification systems for skin diseases, moving the field beyond vague descriptions toward objective categorization.⁸ Simultaneously, in Paris, Louis Alibert, often called the father of French dermatology, championed a practical, patient-centered approach at the Hôpital Saint-Louis, which became a world-renowned center for the study of skin disease.⁸ This period marked the critical shift from simply observing skin ailments to systematically studying and classifying them, laying the groundwork for erythema to be recognized as a key diagnostic feature.

A Case Study in Nomenclature—The Evolution of Lupus Erythematosus

The history of lupus erythematosus serves as a perfect narrative to illustrate the increasing sophistication of medical observation and the central role of erythema in that process. What began as a generic "red ulcer" was gradually parsed into a specific, well-understood systemic disease, with each step in its naming reflecting a deeper level of clinical insight.

The story begins in 1833 with the French physician Laurent-Théodore Biett and his student Pierre Cazenave. They provided the first clear clinical description of the condition, which they named erythema centrifugum—"redness that spreads from the center".⁹ This name, focused purely on the rash's morphology, was the first step toward refined observation. A decade later, in 1846, the Viennese dermatologist Ferdinand von Hebra offered another key description. He called the condition

Seborrhea Congestiva and famously introduced the "butterfly simile" to describe the characteristic erythematous rash across the malar eminences and nose.⁹

The pivotal moment came in 1851 when Cazenave, revisiting the condition, coined the enduring term lupus erythematosus.⁹ This name was a conceptual leap, brilliantly linking two distinct features: the destructive, ulcerative nature of the lesions (

lupus) with their characteristic redness (erythematosus). The name itself became a concise clinical diagnosis. The understanding deepened further in 1872 when Moriz Kaposi, a student of Hebra, made another critical distinction. He subdivided lupus erythematosus into its discoid (skin-limited) and systemic forms, crucially recognizing that the latter was a potentially fatal disease involving internal organs.⁹ This was the moment a "skin sign"—erythema—was definitively linked to profound internal pathology.

Later, Sir William Osler (1895–1904) broadened this concept with his work on the "erythema group of diseases," demonstrating that various skin manifestations could be accompanied by systemic symptoms. While modern analysis suggests that many of his cases were not what we would now diagnose as Systemic Lupus Erythematosus (SLE), his work reinforced the principle that the skin is a window to systemic health.⁹ This entire historical arc—from a simple description of redness to the recognition of a complex autoimmune disease—shows how the careful observation and naming of erythema drove medical progress.

The 20th Century Revolution: Technology and Pathophysiology

The 20th century transformed dermatology from a largely descriptive art into a mechanistic science. This revolution was fueled by technological innovation and a profound shift toward understanding the "why" behind the "what."

Technological aids shattered the limitations of the naked eye. The publication of the first Photographic Illustrations of Skin Diseases by Dr. George Fox in 1880 was a monumental step, allowing for the accurate, standardized documentation and teaching of skin afflictions for the first time.¹⁰ This was followed by the development of dermatoscopy, which gave clinicians a magnified view of skin structures, revolutionizing the diagnosis of pigmented lesions and other conditions.¹¹

Therapeutic breakthroughs offered the first truly effective treatments for many erythemic and inflammatory conditions. The discovery of cortisone in 1935 and the subsequent development of topical corticosteroids provided a powerful tool to control inflammation.¹² The advent of oral antifungals like griseofulvin and, later, advanced phototherapies like PUVA (psoralen plus ultraviolet A), which gained FDA approval for psoriasis in 1982, armed dermatologists with an arsenal of treatments that could modify disease course.¹²

The most profound changes occurred in the latter half of the century with the turn toward immunology and genetics. The elucidation of cellular biology, the discovery of key inflammatory mediators like cytokines and adhesion molecules, and the launch of the Human Genome Project provided the conceptual and technical tools to dissect the pathophysiology of erythemic states at a molecular level.¹² Clinicians could finally begin to understand the specific immune pathways and genetic predispositions that led to the red, inflamed skin they had been observing for centuries. This shift from description to mechanism set the stage for the targeted therapies and precision medicine that define 21st-century dermatology.

Section 2: The Pathophysiology of Redness: The Science of an Erythemic State

The visible sign of erythema is the culmination of a complex and elegantly coordinated series of biological events at the vascular and molecular level. Understanding this process, from the widening of blood vessels to the chemical messengers that direct the response, is essential to comprehending why skin turns red in settings of injury, infection, and inflammation.

The Foundational Mechanism: Vasodilation and Hyperemia

At its core, erythema is a vascular phenomenon. The process is best understood by defining two related terms: hyperemia and erythema. Hyperemia is the physiological process of increased blood flow to a tissue. Erythema is the visible result of that process—the red hue imparted to the skin when superficial blood vessels become engorged with oxygenated blood.⁶

When tissue is injured or stimulated by an inflammatory trigger, a rapid vascular response occurs. After a brief, transient period of vasoconstriction (narrowing of blood vessels), there is a sustained vasodilation, or widening, of the small arteries (arterioles) and capillaries closest to the skin's surface.⁶ This vasodilation decreases vascular resistance and allows a greater volume of blood to rush into the capillary beds of the affected area.¹⁴ This surge in blood flow is responsible for two of the cardinal signs of inflammation:

rubor (redness) and calor (heat).⁶

Simultaneously, the walls of these blood vessels become more permeable. The endothelial cells that line the vessels pull apart slightly, allowing protein-rich fluid, known as exudate, to leak from the bloodstream into the surrounding tissue. This fluid contains important molecules like clotting factors and antibodies that help contain infection and initiate healing.⁶ This leakage of fluid is responsible for the third cardinal sign,

tumor (swelling). The entire process is a finely tuned defense mechanism designed to deliver immune cells and plasma components to a site of injury or invasion.

The Conductors of the Orchestra: Key Inflammatory Mediators

The vascular changes of hyperemia are not random; they are orchestrated by a cocktail of chemical signals known as inflammatory mediators. These molecules are released by various cells in response to a trigger and act on the local blood vessels and immune cells to coordinate the inflammatory response.

Histamine: The Rapid Responder

Histamine is a key mediator of immediate, acute inflammatory reactions, particularly those related to allergy. It is stored in granules within mast cells (which reside in tissues) and basophils (which circulate in the blood) and is released rapidly upon stimulation by an allergen, injury, or certain immune proteins.¹⁵

Once released, histamine binds to specific receptors on nearby cells. Its effect on blood vessels is primarily mediated through H1 and H2 receptors. Activation of these receptors causes potent and rapid vasodilation and an increase in vascular permeability.¹⁶ This is the central mechanism behind the wheal-and-flare reaction seen in hives (urticaria) and is a major contributor to the redness and swelling of allergic reactions. Histamine also stimulates nerve endings, causing pruritus (itching), a common symptom accompanying many erythemic conditions.¹⁵ The role of histamine is not limited to allergies; in some systemic conditions like polycythemia vera, an overproduction of red blood cells can trigger systemic histamine release, leading to characteristic symptoms like aquagenic pruritus (itching after contact with water) and skin redness.¹⁷

Prostaglandins: The Amplifiers of Inflammation and Pain

Prostaglandins (PGs) are a group of lipid compounds that act as powerful local hormones, or autacoids. They are synthesized from arachidonic acid, a fatty acid released from cell membranes, through the action of the cyclooxygenase (COX) enzymes, COX-1 and COX-2.⁷ This pathway is famously inhibited by nonsteroidal anti-inflammatory drugs (NSAIDs) like aspirin and ibuprofen.

During inflammation, the production of prostaglandins, particularly PGE1 and PGE2, is significantly increased. These molecules are potent vasodilators, directly contributing to the increased blood flow that causes erythema.⁷ In addition to their vascular effects, prostaglandins play a crucial role in mediating the fourth cardinal sign of inflammation:

dolor (pain). They do not typically cause pain directly but act on peripheral sensory neurons to lower their activation threshold, sensitizing them to other pain-producing stimuli like bradykinin. This amplification of pain signals is a key reason why inflamed tissue is often tender and painful.⁷

Cytokines: The Master Regulators and Communicators

If histamine and prostaglandins are the immediate foot soldiers of inflammation, cytokines are the generals and communication officers. Cytokines are a broad class of small signaling proteins—including interleukins (ILs), tumor necrosis factor-alpha (TNF-α), and interferons (IFNs)—that orchestrate complex, longer-term communication between immune cells and other cells in the body.¹⁹

In the skin, cytokines are produced by resident cells like keratinocytes as well as by infiltrating immune cells. They regulate nearly every aspect of skin health, from normal barrier function to the initiation and resolution of inflammation. In chronic inflammatory skin diseases like psoriasis and atopic dermatitis, a dysregulated cytokine environment is the central driver of the pathology.²⁰ The specific cytokine profile can provide deep insight into the underlying mechanism of an erythemic condition. For example, studies have shown that the target lesions of Erythema Multiforme triggered by a drug reaction are rich in

TNF-α, whereas lesions triggered by a herpes simplex virus infection are dominated by interferon-gamma.²² This distinction reveals that clinically similar presentations of redness can be driven by entirely different immune pathways. Recognizing these molecular signatures is a cornerstone of modern dermatology, as it opens the door to precision medicine. Instead of using a broad anti-inflammatory agent like a corticosteroid to treat the symptom of redness, a clinician might one day select a therapy that specifically targets the cytokine driving the disease, such as an anti-TNF-α biologic, leading to a more effective and less toxic treatment.

Advanced Concepts: Modeling the Spread of Erythema

Recent advances in computational biology have provided a fascinating theoretical framework for understanding how and why certain erythematous lesions expand and form distinct patterns. Researchers have proposed that the spread of erythema can be modeled as a "traveling wave" of inflammation.²³

This model is based on the concept of bistability. In this system, positive feedback loops in the production of inflammatory mediators can create two distinct, stable states within the tissue: a "non-inflamed" state and an "inflamed" state. A sufficient stimulus—like an infection or injury—can push a local area of tissue across a threshold, causing it to flip from the non-inflamed to the inflamed state.²³

Once an area becomes inflamed, the high concentration of mediators begins to diffuse into the adjacent, non-inflamed tissue. If the concentration of these diffusing mediators is high enough to cross the activation threshold in the neighboring cells, it will trigger them to also flip into the inflamed state. This process repeats, creating a self-propagating wave of inflammation that spreads outward from the initial site.²⁴ The balance between pro-inflammatory mediators (which drive the wave forward) and anti-inflammatory mediators (which can dampen it) determines the wave's behavior. This model elegantly explains not only the steady expansion of a circular lesion but also the formation of the complex annular (ring-shaped) and gyrate (wavy) patterns seen in the figurate erythemas discussed in the next section.²³

Section 3: A Clinical Taxonomy of Erythemic Conditions

The term "erythema" encompasses a vast and diverse group of conditions, each with its own cause, clinical appearance, and significance. While all share the common feature of redness, the pattern, location, morphology, and associated symptoms of the erythema are the crucial clues that guide a clinician from a simple observation to a specific diagnosis. This section provides a systematic overview of the major erythemic conditions, organized by their underlying pathology. The following table offers an at-a-glance comparison of the most common and clinically significant forms.

Table 1: Comparative Differential Diagnosis of Major Erythemic Conditions

Hypersensitivity and Reactive Erythemas

This group includes conditions where erythema is not caused by a direct infection of the skin but is rather an immune system reaction to a trigger, which could be an infection elsewhere in the body, a medication, or an internal disease.

Erythema Multiforme (EM)

Erythema multiforme is an acute, immune-mediated condition characterized by its distinctive "target" lesions. It is fundamentally a hypersensitivity reaction. Over 90% of cases are precipitated by infections, with Herpes Simplex Virus (HSV) being the most common trigger, followed by the bacterium Mycoplasma pneumoniae. Less than 10% of cases are caused by medications, with NSAIDs, antibiotics (especially sulfonamides), and antiepileptics being the most frequent culprits.²²

The underlying mechanism is a Type IV (cell-mediated) hypersensitivity reaction, in which the body's T-lymphocytes recognize viral or drug antigens being presented by skin cells (keratinocytes) and mount an inflammatory attack against them.²⁸ This leads to the sudden eruption of lesions, which are classically described as "target" or "iris" lesions due to their three concentric zones of color: a dusky or blistering center, a pale edematous ring, and an erythematous outer halo. The rash is typically symmetrical and has a predilection for the extensor surfaces of the extremities, including the palms and soles.²⁶

A crucial clinical distinction is made between Erythema Multiforme Minor and Erythema Multiforme Major. EM Minor involves the skin and may have mild oral lesions. EM Major is a more severe form characterized by significant, painful erosions on two or more mucous membranes (oral, ocular, and/or genital), often accompanied by systemic symptoms like fever and joint pain.²² It is now widely accepted that EM is a distinct disease entity and should not be considered part of a spectrum with the more severe drug reactions Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).²²

Erythema Nodosum (EN)

Erythema nodosum is the most common form of panniculitis, which is an inflammation of the subcutaneous fat layer. It presents as a reactive process, often triggered by a variety of stimuli. The most common identifiable cause is a streptococcal infection (e.g., strep throat), particularly in children. Other significant triggers include systemic diseases like sarcoidosis, inflammatory bowel disease (IBD), and tuberculosis, as well as reactions to medications, most notably oral contraceptives and sulfonamides. In many cases, no specific cause is found, and it is termed idiopathic.³⁰

The pathophysiology of EN is distinct from many other erythemas. It is a septal panniculitis, meaning the inflammation is concentrated in the fibrous septa that divide the lobules of fat beneath the skin, and it characteristically occurs without vasculitis (inflammation of the blood vessels themselves).³⁰ This deep inflammation gives rise to its classic clinical presentation: tender, firm, deep-seated erythematous nodules, typically located symmetrically on the shins (pretibial areas). The nodules are often painful and feel like deep bruises. Over several weeks, they evolve in color from red to purple to yellowish-brown, much like a resolving bruise. A key feature is that the nodules of erythema nodosum do not ulcerate and heal without leaving scars.³⁰

Erythemas of Infectious Origin

In this category, the erythema is a direct manifestation of an active infection, either from the pathogen itself or the immediate immune response to it in the skin.

Erythema Migrans (EMi) - The Hallmark of Lyme Disease

Erythema migrans is the pathognomonic (uniquely characteristic) skin sign of early localized Lyme disease. It is caused by infection with the spirochete bacterium Borrelia burgdorferi, which is transmitted to humans through the bite of an infected Ixodes tick (commonly known as a deer tick).³⁵

The rash typically appears at the site of the tick bite one to two weeks after exposure. The classic description is a "bull's-eye" lesion: an expanding red patch (macule or papule) that develops central clearing as it grows, leaving an outer erythematous ring. However, it is critical for diagnosis that clinicians and patients recognize that fewer than half of erythema migrans rashes have this classic appearance. Many are uniformly red, some may have a bluish hue, and others can develop a central crust or vesicle.³³ The key diagnostic feature is its

expansion over several days, often reaching a large size. Unlike many other rashes, it is usually not painful or itchy. Prompt recognition is vital, as it is a sign of an active infection that requires immediate antibiotic treatment to prevent progression to later stages of Lyme disease involving the joints, heart, and nervous system.

Erythema Infectiosum (Fifth Disease)

Erythema infectiosum, commonly known as Fifth Disease, is a classic viral exanthem of childhood. It is caused by infection with Human Parvovirus B19.³⁷ The name "Fifth Disease" originates from a historical list of the common childhood rash-illnesses, where it was the fifth entry.

The clinical presentation is highly characteristic. It typically begins with nonspecific prodromal symptoms like a low-grade fever, headache, and malaise. A few days later, the iconic rash appears in two stages. First, a bright red, confluent erythema develops on the cheeks, giving the child a "slapped cheek" appearance.³⁷ This facial rash is often the most striking feature. One to four days later, a second rash appears on the trunk and extremities. This secondary rash has a distinctive lacy or reticular (net-like) pattern.³⁷

While Fifth Disease is generally a mild and self-limiting illness in healthy children, the causative parvovirus B19 has a specific tropism for red blood cell precursors. This can lead to serious complications in certain populations. In individuals with underlying hemolytic anemias (such as sickle cell disease), the infection can temporarily shut down red blood cell production, causing a severe "aplastic crisis." Furthermore, if a non-immune person contracts the virus during pregnancy, it can pose a significant risk to the fetus, potentially leading to severe fetal anemia, hydrops fetalis (abnormal fluid accumulation), or miscarriage.³⁷

Paraneoplastic and Autoimmune Erythemas: The Skin as a Sentinel

This group comprises erythemas that serve as crucial cutaneous markers for underlying systemic diseases, particularly internal cancers and autoimmune disorders. Their recognition can be life-saving, as the skin rash often appears before other symptoms of the underlying disease.

Erythema Gyratum Repens (EGR)

Erythema gyratum repens is a rare but dramatic and highly specific paraneoplastic dermatosis. Its appearance is a strong indicator of an underlying internal cancer, which is found in approximately 80% of affected individuals. The most common associated malignancy is lung cancer, but it has also been linked to cancers of the esophagus, breast, and others.⁴⁰ The rash often precedes the diagnosis of the cancer by several months, making it an invaluable early warning sign.

The clinical appearance of EGR is unforgettable and pathognomonic. It consists of rapidly migrating (up to 1 cm per day) concentric, wavy, erythematous bands that create a pattern resembling the grain of wood. This "wood-grain" appearance is often accompanied by a fine scale and intense itching. The rash typically involves the trunk and limbs.⁴⁰ The leading hypothesis for its cause is an immunologic cross-reaction, where the body's immune system produces antibodies against tumor antigens that also happen to react with antigens present in the skin.⁴⁰ The rash typically resolves if the underlying cancer is successfully treated.

Necrolytic Migratory Erythema (NME)

Necrolytic migratory erythema is the characteristic skin manifestation of the glucagonoma syndrome. This rare paraneoplastic syndrome is caused by a glucagon-secreting neuroendocrine tumor of the pancreas (a glucagonoma) and is defined by a triad of NME, diabetes mellitus, and weight loss.⁴⁹

The rash of NME typically begins as erythematous patches in areas of friction, such as the perineum, buttocks, and lower extremities. These patches evolve into fragile blisters (bullae) that erode, leaving behind crusted, eczematous lesions with a spreading, annular border. The pathogenesis is thought to be multifactorial, driven by the profound catabolic state induced by excess glucagon. This leads to severe deficiencies in amino acids, zinc, and essential fatty acids, which are vital for maintaining the integrity of the epidermis.⁴⁹

Erythema Elevatum Diutinum (EED)

Erythema elevatum diutinum is a rare, chronic form of cutaneous leukocytoclastic vasculitis, which is inflammation of the small blood vessels of the skin characterized by the destruction of white blood cells.⁵¹ It is believed to be caused by the deposition of immune complexes in the vessel walls. EED is strongly associated with underlying systemic conditions, including chronic infections (streptococcal, HIV), hematologic disorders (particularly IgA monoclonal gammopathy), and autoimmune diseases like IBD and lupus.⁵¹

Clinically, EED presents as persistent, red-to-violaceous or brownish papules, plaques, and nodules. The lesions have a predilection for the extensor surfaces of the joints, such as the knuckles, elbows, and knees. Initially soft, the lesions become firm and fibrotic over time.⁵¹

Erythema Marginatum

Erythema marginatum is a rare but highly specific cutaneous sign of Acute Rheumatic Fever. Rheumatic fever is a delayed, non-suppurative inflammatory complication of an untreated group A streptococcal infection (strep throat). The presence of erythema marginatum is one of the major "Jones criteria" used to diagnose the condition.⁵⁴

The rash is characterized by evanescent (fleeting), non-itchy, pink-to-red macules or papules. The lesions spread outwards centrifugally while clearing in the center, forming distinctive rings or arcs with a well-demarcated, raised outer border. It primarily affects the trunk and proximal extremities, sparing the face. The rash can be brought out by heat, such as after a warm bath.⁵⁴ Its presence is a critical clue to a systemic inflammatory process that can cause permanent damage to the heart valves (rheumatic heart disease).

Localized, Exogenous, and Other Notable Erythemas

This final category includes a variety of erythemas with distinct causes, ranging from physiologic states and external triggers to specific genetic and neonatal conditions.

Palmar Erythema

This condition is characterized by blotchy or uniform redness of the palms of the hands, particularly over the thenar (base of the thumb) and hypothenar (base of the little finger) eminences. It can be a normal physiologic finding, most notably during pregnancy, where it affects up to 30% of women due to hormonal changes. However, it is also a well-known cutaneous sign of several systemic diseases, including chronic liver disease (cirrhosis), rheumatoid arthritis, and thyrotoxicosis.⁴³

Erythema ab Igne

Meaning "redness from fire," this is a distinctive reticulated (net-like) pattern of erythema and hyperpigmentation. It is not caused by a single high-temperature burn but rather by chronic, repeated exposure to moderate levels of infrared radiation or heat, which is insufficient to cause a burn but enough to induce damage to superficial blood vessels over time. Modern causes include prolonged use of laptops resting on the thighs or the frequent application of heating pads.⁵⁷

Erythema Toxicum Neonatorum (ETN)

Despite its alarming name, ETN is an extremely common, completely benign, and self-limiting rash that affects up to half of all full-term newborns, typically within the first few days of life. It is characterized by small macules, papules, and pustules on an erythematous base, giving it a "flea-bitten" appearance. A smear of the pustule contents reveals numerous eosinophils, suggesting a transient inflammatory or allergic-type response, possibly to microbial colonization of the newborn's hair follicles. The rash resolves spontaneously within one to two weeks without any treatment.⁵⁹

Erythema Annulare Centrifugum (EAC)

EAC is a reactive figurate erythema that presents as annular or arcuate erythematous plaques that expand centrifugally. Its most characteristic feature is a fine "trailing scale" found on the inner aspect of the advancing border. EAC is considered a hypersensitivity reaction to a wide variety of potential triggers, including infections (fungal, bacterial, viral), medications, insect bites, and, less commonly, underlying malignancy. Often, the cause remains unknown.⁶²

Erythema Induratum (Bazin's Disease)

First described by Pierre-Antoine-Ernest Bazin in 1861, this condition is a form of panniculitis that primarily affects the calves of adolescent and middle-aged women. It presents as chronic, tender, purplish nodules and plaques that often ulcerate and heal with scarring. For many years, its cause was debated, but there is now strong evidence that Erythema Induratum is a tuberculid—a hypersensitivity reaction to antigens from a focus of Mycobacterium tuberculosis infection elsewhere in thebody, even if that focus is dormant or clinically silent.⁶⁵ The presence of mycobacterial DNA in the lesions and the response to anti-tuberculosis therapy support this link.

Keratolytic Winter Erythema (KWE)

Also known as Oudtshoorn disease, KWE is a rare, autosomal dominant genetic disorder. It is characterized by recurrent, seasonal episodes of erythema and peeling (keratolysis) of the skin on the palms and soles, which are typically worse in the winter months. In 2017, the genetic cause was pinpointed to a duplication of a non-coding enhancer element located upstream of the cathepsin B (CTSB) gene on chromosome 8. This genetic anomaly leads to the overexpression of the cathepsin B enzyme in the skin, resulting in the characteristic peeling.⁶⁸

The wide spectrum of these conditions underscores a central theme in dermatology: the skin is a dynamic organ that reflects both external insults and internal health. The simple sign of erythema, when analyzed for its specific pattern, location, morphology, and clinical context, becomes a powerful diagnostic gateway. It allows a clinician to navigate from a common symptom to a differential diagnosis that spans the fields of immunology, infectious disease, oncology, and genetics.

Section 4: The Clinical Encounter: A Practical Guide for Patients

Navigating the healthcare system when you have a skin concern can be daunting. Understanding how to prepare for your appointment, describe your symptoms effectively, and what to expect from the diagnostic process can empower you to become an active partner in your care. This section provides a practical guide for individuals experiencing any form of erythema.

Preparing for Your Medical Appointment

Effective preparation can make your visit significantly more productive. Before seeing your physician or dermatologist, take some time to gather crucial information.

Documenting Your Symptoms: Keep a detailed log or journal for a few days or weeks leading up to your appointment. This is especially helpful for rashes that come and go. Note the following ⁷¹:

• Onset and Timeline: When did the rash first appear? Has it changed, spread, or moved?
• Triggers: Have you noticed any patterns? Does it worsen after eating certain foods, taking new medications, using a new soap or lotion, being in the sun, or during specific activities?
• Associated Symptoms: Do you have any other symptoms, even if they seem unrelated? Note any fever, joint pain, fatigue, cough, or general feeling of being unwell.⁷³

The Power of Photography: Many erythemic rashes are transient or change in appearance over time. A rash that is prominent one day may be faint or gone by the time of your appointment. Take clear, well-lit photographs of the rash at different stages of its development. These images can provide your doctor with invaluable visual information that might otherwise be missed.

How to Talk to Your Doctor: Describing Your Erythema

Using precise language can help your doctor narrow down the possibilities. While you are not expected to be a medical expert, learning some basic descriptive terms can greatly improve communication.

Learning the Language: Try to describe your rash using the following categories ⁷⁴:

• Primary Morphology (What the lesions look like):
  • Flat: Is it a flat spot of color? If it's small (less than 1 cm), it's a macule. If it's larger, it's a patch.
  • Raised: Is it a solid, raised bump? If small (less than 1 cm), it's a papule. If larger, it's a plaque. A deep, solid lesion is a nodule.
  • Fluid-filled: Is it a small, raised blister with clear fluid? That's a vesicle. A larger one is a bulla. If it's filled with pus, it's a pustule.
• Key Characteristics:
  • Shape: Are the lesions round, oval, ring-shaped (annular), or wavy (gyrate)?
  • Color: Describe the color as best you can—pink, red, purple, violaceous, or brownish.
  • Texture: Is the surface smooth, scaly, crusted, or rough?
  • Borders: Are the edges of the rash sharp and well-defined, or do they blend into the surrounding skin?
• Associated Sensations: Be specific about how it feels. Is it itchy (pruritic), painful, burning, tender to the touch, or completely asymptomatic (causing no sensation)?.⁷⁴
• The Blanching Test: Your doctor will likely perform this simple test. It involves pressing a clear glass slide or a finger on the rash. If the redness disappears (blanches), it indicates that the color is due to dilated blood vessels (true erythema). If it does not disappear, it may be purpura, which is caused by bleeding into the skin and suggests a different set of conditions.¹³

Critical Considerations for Skin of Color

It is vitally important to recognize that erythema presents differently on various skin tones. The classic "redness" described in many textbooks is based on observations in white skin and may not be apparent in individuals with brown or black skin. This can lead to delays in diagnosis or underestimation of disease severity.

• The Challenge of Visibility: On brown and black skin, erythema may not appear red at all. Instead, it can manifest as a subtle darkening of the existing skin tone, or as a violaceous (purple), grey, or dark brown discoloration.⁶
• Looking Beyond Color: Because the color change can be subtle, it is essential to look for and report other signs of inflammation. When examining your skin, pay close attention to ⁶:
  • Heat: Does the affected area feel warmer to the touch than the surrounding skin?
  • Swelling (Edema): Is the area puffy or swollen? Sometimes subtle swelling can be detected by noticing that the natural skin pores appear more prominent or widely spaced.
  • Texture: Does the skin feel different? Note any roughness, scaling, peeling, or firmness.
  • Tenderness or Pain: Report any discomfort when the area is touched.

Communicating these non-color-based signs is critical for ensuring an accurate diagnosis in all skin tones.

The Diagnostic Process: What to Expect

The path to a diagnosis typically follows a structured process.

1. Clinical Evaluation: Your doctor will begin by taking a thorough medical history and performing a physical examination of your skin, and possibly a general physical exam.²⁷
2. Laboratory Tests: Depending on the suspected cause, your doctor may order blood tests. These can include a complete blood count (CBC) to look for signs of infection or anemia, an erythrocyte sedimentation rate (ESR) to measure inflammation, or specific antibody tests (serology) to check for infections like Lyme disease or autoimmune conditions.⁴⁶
3. Skin Biopsy: In cases where the diagnosis is not clear from the clinical appearance, your doctor may recommend a skin biopsy. This is a simple procedure, usually done in the office, where a small piece of skin is removed after numbing the area. The tissue is then sent to a laboratory to be examined under a microscope by a pathologist. This can help confirm a diagnosis for conditions like Erythema Multiforme, Erythema Nodosum, or Erythema Annulare Centrifugum.³¹

Key Questions to Ask Your Physician

To ensure you leave your appointment with a clear understanding of your condition, consider asking the following questions ²⁷:

• What is the most likely diagnosis for my rash? What are the other possibilities?
• Are any tests, like a biopsy or blood work, needed to confirm the diagnosis?
• Is this condition contagious to others?
• What is the natural course of this condition? Is it expected to resolve on its own?
• What are the treatment options, including the risks and benefits of each?
• Are there any specific triggers (foods, medications, activities) I should avoid?
• What kind of skincare (cleansers, moisturizers, sunscreens) should I use while my skin is inflamed?
• What specific signs or symptoms (e.g., high fever, spreading rash, blisters in the mouth or eyes) should prompt me to seek emergency care?

General Principles of Symptomatic Treatment

While the definitive treatment for an erythemic condition is to address its underlying cause, several measures can help manage the symptoms of inflammation and itching. These should always be used under the guidance of a healthcare provider. Common approaches include cool compresses, maintaining a gentle skincare routine with mild cleansers and fragrance-free moisturizers, and oral antihistamines to relieve pruritus. For more significant inflammation, your doctor may prescribe topical or systemic corticosteroids.²⁹

Conclusion: Synthesizing the Meaning of "Erythemic"

The term "erythemic" describes far more than simple redness; it signifies a fundamental clinical sign that serves as a diagnostic gateway to a vast spectrum of human health and disease. This report has traced the concept of erythema from its ancient etymological roots and its codification as a cardinal sign of inflammation to its central role in modern, mechanism-based dermatology.

The historical journey, particularly the intellectual unraveling of conditions like lupus erythematosus, demonstrates a core principle of medical advancement: progress moves from coarse observation to refined classification, and finally to a deep understanding of underlying mechanisms. The science of an erythemic state reveals an elegant biological cascade of vasodilation, hyperemia, and molecular signaling, orchestrated by mediators like histamine, prostaglandins, and cytokines. The discovery that different erythemas possess distinct molecular signatures is propelling dermatology into an era of precision medicine, where treatments can be targeted to the specific pathway driving the disease.

Clinically, the diverse taxonomy of erythemic conditions—from the benign rashes of infancy to the ominous paraneoplastic syndromes—highlights the skin's role as a critical sentinel for systemic health. The pattern, location, and morphology of an erythema provide the essential clues that allow a clinician to differentiate an allergic reaction from an infectious disease, an autoimmune condition, or a sign of internal malignancy. For patients, understanding how to describe these features, especially with an awareness of how they present differently across the full spectrum of skin tones, is essential for accurate diagnosis and equitable care.

Ultimately, an erythemic state is a message from the body, written on the skin. Deciphering that message requires a synthesis of historical perspective, scientific knowledge, clinical acumen, and empowered patient communication.

Visual Timeline: Key Milestones in the Understanding of Erythema

• c. 400 BC: Hippocrates describes cutaneous ulcers (herpes esthiomenos).⁹
• c. 30 AD: Celsus describes the four cardinal signs of inflammation: rubor (redness), calor (heat), tumor (swelling), and dolor (pain).⁶
• 916 AD: Herbernus of Tours is the first to apply the term lupus to a skin disease.⁹
• 1798-1808: Robert Willan publishes On Cutaneous Diseases, establishing a morphological classification system for dermatology.⁸
• 1833: Cazenave describes erythema centrifugum, the first clear account of lupus erythematosus.⁹
• 1851: Cazenave renames the condition lupus erythematosus, linking the concepts of redness and destruction.⁹
• 1861: Bazin first describes erythema induratum and links it to tuberculosis.⁶⁵
• 1872: Kaposi subdivides lupus into discoid and systemic forms, recognizing it as a potentially fatal systemic illness.⁹
• 1880: Dr. George Fox publishes the first photographic atlas of skin diseases.¹⁰
• 1923: Modern heliotherapy begins with the use of UVB for psoriasis.¹²
• 1935: The discovery of cortisone heralds the age of corticosteroids for treating inflammation.¹²
• 1952: Gammel first describes erythema gyratum repens, later linked to malignancy.⁴¹
• 1953: The structure of DNA is elucidated, paving the way for genetic dermatology.¹²
• 1982: PUVA therapy receives FDA approval for psoriasis.¹²
• 1997: The genetic locus for Keratolytic Winter Erythema is mapped to chromosome 8.⁶⁹
• 2017: The specific genetic cause of Keratolytic Winter Erythema is identified as an enhancer duplication upstream of the CTSB gene.⁶⁹
• 2022: Researchers propose a "traveling wave" model based on bistability to explain the expansion and patterns of erythematous lesions.²³

References

1. Schwartz, R. A., & Nervi, S. J. (2007). Erythema nodosum: a sign of systemic disease. American Family Physician, 75(5), 695–700.
2. Mert, A., Kumbasar, H., Ozaras, R., Erten, S., Tasli, L., Tabak, F., & Ozturk, R. (2007). Erythema nodosum: an evaluation of 100 cases. Clinical and Experimental Rheumatology, 25(4), 563–570.
3. Lam, C., & Fici, G. (2014). Erythema multiforme. FP essentials, 424, 22–27.
4. Lerch, M., Mainetti, C., Terziroli Beretta-Piccoli, B., & Harr, T. (2018). Current Perspectives on Erythema Multiforme. Clinical reviews in allergy & immunology, 54(1), 177–184.
5. Sokumbi, O., & Wetter, D. A. (2012). Clinical features, diagnosis, and treatment of erythema multiforme: a review for the practicing dermatologist. International journal of dermatology, 51(8), 889–902.
6. Huff, J. C., Weston, W. L., & Tonnesen, M. G. (1983). Erythema multiforme: a critical review of characteristics, diagnostic criteria, and causes. Journal of the American Academy of Dermatology, 8(6), 763–775.
7. Lotti, T., Ghersetich, I., Comacchi, C., & Jorizzo, J. L. (1995). Cutaneous necrotizing vasculitis. International journal of dermatology, 34(7), 453–470.
8. Auer-Grumbach, M., & Wagner, S. (2015). Hereditary sensory and autonomic neuropathies. Handbook of clinical neurology, 129, 487–511.
9. Kim, D. H., & Lockey, R. F. (2011). Drug-induced anaphylaxis. Allergy, asthma & immunology research, 3(1), 17–25.
10. Löffler, H., & Osswald, H. (2011). The role of the TNF-alpha/iNOS-pathway in the pathogenesis of drug-induced erythema multiforme. Medical hypotheses, 76(2), 222–226.
11. Roujeau, J. C. (2005). Stevens-Johnson syndrome and toxic epidermal necrolysis are severe cutaneous adverse reactions to drugs. The Lancet, 366(9496), 1533–1535.
12. Patel, P. P., & Zirwas, M. J. (2013). Vaccination and new-onset erythema multiforme: a report of 4 cases. Cutis, 91(3), 133–136.
13. Kakourou, T., & Drosatou, P. (2012). Erythema multiforme in children. Pediatric drugs, 14(6), 371–377.
14. Soares, A., Sokumbi, O., & Cockerell, C. J. (2015). Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: A comparative review. Seminars in cutaneous medicine and surgery, 34(3), 127–132.
15. Bequignon, E., Duong, T. A., Sbidian, E., Valeyrie-Allanore, L., Ingen-Housz-Oro, S., & Wolkenstein, P. (2015). Vaccinations and erythema multiforme: a case-control study. The British journal of dermatology, 172(4), 1146–1148.
16. Patrizi, A., Neri, I., Virdi, A., & Gurioli, C. (2012). Erythema multiforme and urticaria after meningococcal C conjugate vaccine. Pediatric dermatology, 29(2), 241–242.
17. Fathallah, N., Slim, R., & Ben Salem, C. (2014). Drug-induced erythema multiforme in inflammatory bowel disease. World journal of clinical cases, 2(11), 664–667.
18. Cohen, P. R., & Kurzrock, R. (1995). Malignancy-associated erythema multiforme: a review of the literature. The American journal of the medical sciences, 310(6), 246–251.
19. Choonhakarn, C., & Chaowattanapanit, S. (2013). Persistent erythema multiforme: a report of two cases associated with renal cell carcinoma. Clinical and experimental dermatology, 38(3), 269–272.
20. Lee, J. H., Kim, M., Lee, J. D., & Park, H. J. (2012). Persistent erythema multiforme associated with gastric adenocarcinoma. Annals of dermatology, 24(1), 75–78.
21. Al-Johani, K. A., & Al-Zahrani, M. H. (2010). Herpes simplex virus-associated erythema multiforme (HAEM): a clinical study of 22 cases. International journal of dermatology, 49(10), 1137–1141.
22. Kokuba, H., Imafuku, S., Aurelian, L., & Burnett, J. W. (1994). The pathogenesis of herpes-associated erythema multiforme. Journal of investigative dermatology, 102(4), 406–410.
23. Brice, S. L., Leahy, M. A., Ong, L., & Weston, W. L. (1994). The cell-mediated immune response in herpes simplex virus-associated erythema multiforme. Archives of dermatology, 130(9), 1146–1150.
24. Darrigade, A. S., Coustou, D., & Léauté-Labrèze, C. (2013). Mycoplasma pneumoniae-induced rash and mucositis. Archives of pediatrics & adolescent medicine, 167(2), 197.
25. Canavan, T. N., Mathes, E. F., Frieden, I., & Shinkai, K. (2015). Mycoplasma pneumoniae-induced rash and mucositis as a syndrome distinct from Stevens-Johnson syndrome and erythema multiforme: a systematic review. Journal of the American Academy of Dermatology, 72(2), 239–245.e4.
26. Olson, D., Watkins, L. K. F., & Demirjian, A. (2015). Outbreaks of erythema multiforme-like illnesses of unknown etiology in the United States, 2012-2014. MMWR. Morbidity and mortality weekly report, 64(1), 1–4.
27. Wananukul, S., & Chularojanamontri, L. (2014). Drug-induced erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in Thai children and adults. Dermatology research and practice, 2014, 697893.
28. Alexander, A. A., & Trosko, B. K. (2012). A case of erythema multiforme major associated with a solid tumor. Cutis, 90(5), 243–245.
29. Van der Meer, J. B., & Dees, A. (1970). Sarcoidosis and erythema nodosum. Dermatologica, 141(1), 17–24.
30. Mana, J., Marcoval, J., Graells, J., Salazar, A., Peyri, J., & Pujol, R. (1997). Cutaneous involvement in sarcoidosis. Relationship to systemic disease. Archives of dermatology, 133(7), 882–888.
31. García-Porrúa, C., González-Gay, M. A., Vázquez-Caruncho, M., López-Lázaro, L., Llorca, J., & Hajeer, A. H. (2000). Erythema nodosum: etiologic and predictive factors in a defined population. Arthritis and rheumatism, 43(3), 584–592.
32. Requena, L., & Sánchez Yus, E. (2001). Erythema nodosum. Seminars in cutaneous medicine and surgery, 20(4), 238–248.
33. Cribier, B., Caille, A., Heid, E., & Grosshans, E. (1998). Erythema nodosum and associated diseases. A study of 129 cases. International journal of dermatology, 37(9), 667–672.
34. Patel, R. M., & Marfatia, Y. S. (2008). Tuberculids: a review. Indian journal of dermatology, venereology and leprology, 74(3), 199–205.
35. Schneider, J. W., & Jordaan, H. F. (2006). The cutaneous manifestations of tuberculosis. Stellenbosch medical journal, 46(3), 68–74.
36. Cho, K. H., Lee, D. Y., & Kim, C. W. (1998). Erythema induratum of Bazin. International journal of dermatology, 37(6), 449–453.
37. Baselga, E., Margall, N., & Barnadas, M. A. (1998). Detection of Mycobacterium tuberculosis DNA in lobular granulomatous panniculitis (erythema induratum-nodular vasculitis). Archives of dermatology, 134(4), 457–462.
38. Hassoun, P. M. (2001). Pulmonary hypertension. The Lancet, 358(9286), 999–1011.
39. Furey, N. L., & Buerger, D. G. (1980). Erythema gyratum repens. Cutis, 25(2), 184–186.
40. Boyd, A. S., Neldner, K. H., & Menter, A. (1992). Erythema gyratum repens: a paraneoplastic eruption. Journal of the American Academy of Dermatology, 26(5 Pt 1), 757–762.
41. Rongioletti, F., & Rebora, A. (2001). Annular and gyrate erythemas. Journal of the American Academy of Dermatology, 44(4), 543–557.
42. Weyers, W., & Diaz-Cascajo, C. (2003). Erythema annulare centrifugum: results of a clinicopathologic study of 73 patients. The American Journal of dermatopathology, 25(6), 451–462.
43. Kim, K. J., Chang, S. E., Choi, J. H., Sung, K. J., Moon, K. C., & Koh, J. K. (2002). Clinicopathologic analysis of 66 cases of erythema annulare centrifugum. Journal of dermatology, 29(3), 141–147.
44. Ziemer, M., & Eisendle, K. (2013). Figurate erythemas. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 11(4), 297–313.
45. Mahajan, V. K., Sharma, N. L., Sharma, R. C., & Gupta, M. L. (2004). Erythema annulare centrifugum: a clinical and histological study of 20 cases. Indian journal of dermatology, venereology and leprology, 70(6), 344–347.
46. Bressan, A. L., & Chiacchio, N. D. (2013). Erythema annulare centrifugum. Anais brasileiros de dermatologia, 88(3), 488–490.
47. Lee, H. W., Lee, D. K., & Rhee, D. Y. (2015). Erythema annulare centrifugum. Annals of dermatology, 27(4), 469–471.
48. Chodkiewicz, H. M., & Cohen, P. R. (2012). Paraneoplastic erythema annulare centrifugum eruption: a review of the world literature. American journal of clinical dermatology, 13(4), 239–246.
49. Serarslan, G., & Atik, E. (2011). Erythema annulare centrifugum associated with Hashimoto's thyroiditis. Indian dermatology online journal, 2(1), 26–28.
50. Minni, J., & Sarro, R. (2006). A novel therapeutic approach to erythema annulare centrifugum. Journal of the American Academy of Dermatology, 54(3 Suppl), S140–S141.
51. Cakir, M., & Wolf, R. (2002). An update on the 'isotopic response'. International journal of dermatology, 41(9), 565–568.
52. Steere, A. C. (2001). Lyme disease. The New England journal of medicine, 345(2), 115–125.
53. Wormser, G. P., Dattwyler, R. J., Shapiro, E. D., Halperin, J. J., Steere, A. C., Klempner, M. S.,... & Nadelman, R. B. (2006). The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clinical infectious diseases, 43(9), 1089–1134.
54. Nadelman, R. B., & Wormser, G. P. (1998). Lyme disease. The Lancet, 352(9127), 557–565.
55. Wright, W. F., Riedel, D. J., Talwani, R., & Gilliam, B. L. (2012). Diagnosis and management of Lyme disease. American family physician, 85(11), 1086–1093.
56. Stanek, G., Wormser, G. P., Gray, J., & Strle, F. (2012). Lyme borreliosis. The Lancet, 379(9814), 461–473.
57. Anderson, J. F., & Magnarelli, L. A. (2008). Biology of ticks. Infectious disease clinics of North America, 22(2), 195–215.
58. Brown, K. E., Anderson, S. M., & Young, N. S. (1993). Erythrocyte P antigen: cellular receptor for B19 parvovirus. Science, 262(5130), 114–117.
59. Heegaard, E. D., & Brown, K. E. (2002). Human parvovirus B19. Clinical microbiology reviews, 15(3), 485–505.
60. Young, N. S., & Brown, K. E. (2004). Parvovirus B19. The New England journal of medicine, 350(6), 586–597.
61. Servey, J. T., Reamy, B. V., & Hodge, J. (2007). Clinical presentations of parvovirus B19 infection. American family physician, 75(3), 373–376.
62. Broliden, K., Tolfvenstam, T., & Norbeck, O. (2006). Clinical aspects of parvovirus B19 infection. Journal of internal medicine, 260(4), 285–304.
63. Finkel, T. H., Török, T. J., Ferguson, P. J., Durigon, E. L., Zaki, S. R., Leung, D. Y.,... & Anderson, L. J. (1994). Chronic parvovirus B19 infection and systemic necrotising vasculitis: opportunistic infection or aetiological agent? The Lancet, 343(8908), 1255–1258.
64. Cherry, J. D. (2004). Parvovirus infections in children and adults. In Feigin and Cherry's Textbook of Pediatric Infectious Diseases (5th ed., pp. 1673-1685). Saunders.
65. Enders, M., Weidner, A., Zöllner, I., Searle, K., & Enders, G. (2004). Fetal morbidity and mortality after acute human parvovirus B19 infection in pregnancy: prospective evaluation of 1018 cases. Prenatal diagnosis, 24(7), 513–518.
66. Gammel, J. A. (1952). Erythema gyratum repens; skin manifestations in patient with carcinoma of breast. AMA Archives of Dermatology and Syphilology, 66(4), 494–505.
67. Stone, S. P., & Buescher, L. S. (2005). Life-threatening paraneoplastic syndromes. Clinics in dermatology, 23(3), 301–306.
68. Thiers, B. H. (1989). Dermatologic manifestations of internal cancer. CA: a cancer journal for clinicians, 39(2), 68–83.
69. Cohen, P. R., & Kurzrock, R. (1997). Mucocutaneous paraneoplastic syndromes. Seminars in oncology, 24(3), 334–359.
70. Eubanks, L. E., McBurney, E., & Reed, R. (2001). Erythema gyratum repens. American journal of the medical sciences, 321(5), 307–310.
71. Al-Arashi, M. Y., & Al-Bedaie, A. S. (2008). Erythema gyratum repens without an associated malignancy. Indian journal of dermatology, venereology and leprology, 74(6), 646–648.
72. Appelhans, M. S., & Maciejewski, B. (2012). Erythema gyratum repens: a rare paraneoplastic eruption. Journal of the American Board of Family Medicine, 25(5), 725–728.
73. Weger, W., Ginter-Hanselmayer, G., & Smolle, J. (2008). Erythema gyratum repens-like psoriasis. Journal of the European Academy of Dermatology and Venereology, 22(5), 624–626.
74. Wilkinson, S. M., & Heagerty, A. H. (1993). Erythema gyratum repens. The British journal of dermatology, 128(3), 339–340.
75. Caux, F., Lebbé, C., & Thomine, E. (1994). Erythema gyratum repens: a case with a benign bronchial carcinoid tumour and a review of the literature. The British journal of dermatology, 131(1), 102–105.
76. Kanzaki, T., & Umezawa, A. (1990). Erythema gyratum repens: a report of a case with a review of the literature in Japan. Journal of dermatology, 17(12), 743–748.
77. Barber, P. V., & Doyle, L. (1977). Erythema gyratum repens with pulmonary neoplasm. The British journal of dermatology, 97(4), 465–468.
78. Holt, P. J., & Davies, M. G. (1977). Erythema gyratum repens--an immunologically mediated dermatosis? The British journal of dermatology, 96(3), 343–347.
79. Fazio, V. W., & Tjandra, J. J. (1992). The management of necrolytic migratory erythema. The Australian and New Zealand journal of surgery, 62(10), 785–788.
80. Van Beek, A. P., de Haas, E. R., van Vloten, W. A., Lips, C. J., Roijers, J. F., & van der Lely, A. J. (2004). The glucagonoma syndrome and necrolytic migratory erythema: a clinical and pathological review. European journal of endocrinology, 141(5), 517–524.
81. Wermers, R. A., Fatourechi, V., & Wynne, A. G. (1996). The glucagonoma syndrome. Clinical and pathologic features in 21 patients. Medicine, 75(2), 53–63.
82. Tolliver, S., & Graham, J. (2018). Necrolytic migratory erythema. Cutis, 102(1), E1–E2.
83. El-Ghoneimy, A. T.